Day: February 23, 2026

ATLANTA, GA, Feb. 23, 2026 (GLOBE NEWSWIRE) — Trust Stamp (Nasdaq: IDAI), a global provider of AI-powered trust, identity, and security solutions, today announced will provide IDetect, a leading provider of ID scanning and entrance security solutions for over 25 years, with access to the American Association of Motor Vehicle Administrators (AAMVA) Driver’s License Data Verification (DLDV) service. This capability elevates IDetect’s current suite of document scanning tools, trusted by over 70 industries, including major brands like Marriott, Harrah’s Casinos, and the Federal Bureau of Investigation (FBI), by enabling real-time verification of driver’s license data against official issuing agency records. While traditional ID scanners check for security features on the physical card, the addition of AAMVA DLDV allows IDetect customers...

As part of its strategic shift, Company is divesting retail assets to focus on homeland security and advanced technologies Tel Aviv, Israel, Feb. 23, 2026 (GLOBE NEWSWIRE) — Jeffs’ Brands Ltd (“Jeffs’ Brands” or the “Company”) (Nasdaq: JFBR, JFBRW), a data-driven e-commerce company operating on the Amazon Marketplace expanding into the global homeland security sector through advanced artificial intelligence (“AI”) – driven solutions, today announced the closing of a share transfer agreement dated December 18, 2025 with institutional investors,  to sell and transfer 714,286 common shares of Fort Technology Inc. (TSXV: FORT) (“Fort”), for a total consideration of CAD $928,571 (approximately CAD $1.3 per share). The shares represent approximately 8.1% of Jeffs’ Brands holdings in Fort and approximately 6.3% of Fort’s outstanding...

OCALA, Fla., Feb. 23, 2026 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced milestones in the expected timeline for the ongoing Phase 2 clinical study evaluating AIM’s drug Ampligen® (rintatolimod) combined with AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor Imfinzi® (durvalumab) in the treatment of metastatic pancreatic cancer patients with stable disease post-FOLFIRINOX standard of care (the “DURIPANC” study) (see: ClinicalTrials.gov NCT05927142). DURIPANC is an investigator-initiated, exploratory, open-label, single-center study, and 18 subjects have enrolled in the study so far. The clinical trial is a joint collaboration between AIM, AstraZeneca and Erasmus Medical Center (“Erasmus MC”) in the Netherlands. Planned DURIPANC milestones:July 2026 – Complete subject enrollment. August...

To Nasdaq OMX Copenhagen A/S Company announcement no. 585 February 23rd, 2026 OUTLOOK (GUIDANCE) FOR 2026 The Board of Directors in Glunz & Jensen Holding A/S have reviewed and approved the outlook (guidance) for 2026. HighlightsThe revenue for 2026 is expected at approximately DKK 140 million (outlook for 2025 DKK is at approximately 140 million)The EBITDA for 2026 is expected at approximately DKK 18 million (outlook for 2025 DKK is at approximately 17 million)The profit before tax for 2026 is expected at approximately DKK 12 million (outlook for 2025 DKK is at approximately 11 million)The outlook for 2026 is not affected or impacted by the selling process of Selandia Park A/S. Glunz & Jensen Holding A/S will announce the 2025 annual report on March 17th, 2026. For further information please contact: CEO Henrik Blegvad...

Dr. Anczukow is a leading cancer biologist with expertise in RNA biology, molecular and cell biology, as well as human genetics, cancer biology, and genomicsOlga Anczukow, Ph.D.Olga Anczukow, Ph.D.TAMPA, Fla. and LONDON, Feb. 23, 2026 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel immuno-oncology payloads, today announced the appointment of Olga Anczukow, Ph.D. to its Scientific Advisory Board (SAB). Abizer Gaslightwala, President and Chief Executive Officer of Akari Therapeutics commented, “Dr. Anczukow is a leading authority in RNA splicing and cancer biology, an area of growing importance for the development of next-generation therapeutics. Her scientific rigor, translational mindset, and experience advancing RNA-focused...

Press contact:Mollie MellowsTel.:+ 44 73 42 70 93 84E-mail: mollie.mellows@capgemini.com Capgemini joins forces with OpenAI to accelerate new era of AI-powered enterprise transformation with Frontier Alliance Paris, February 23, 2026 — Capgemini today announced a new strategic partnership with OpenAI to accelerate the next era of enterprise AI transformation with Frontier, OpenAI’s new platform for building, deploying, and managing AI coworkers that can do real work across the enterprise. As a founding member of the OpenAI Frontier Alliance, Capgemini will work to address the AI opportunity gap by focusing on the business, data, organizational, and systems integration challenges faced by clients, to deploy AI enterprise-wide. By combining deep industry and domain-specific process expertise, data and governance capabilities, and ready-to-deploy...

TORONTO, Feb. 23, 2026 (GLOBE NEWSWIRE) — GLOBEX MINING ENTERPRISES INC. (GMX – Toronto Stock Exchange, G1MN – Frankfurt, Stuttgart, Berlin, Munich, Tradegate, Lang & Schwarz, LS Exchange, TTMzero, Düsseldorf and Quotrix Düsseldorf Stock Exchanges and GLBXF – OTCQX International in the US) is pleased to update shareholders on exploration drilling by Cartier Resources Inc. (ECR-TSXV, 6CA-FSE) on Globex’s Nordeau Royalty claims (Exhibit 1) in Vauquelin Township (32C03), 45 km southeast of Val d’Or, Quebec. Globex holds a 3% Gross Metal Royalty on the Nordeau claims including the area where Cartier has identified a new gold zone called the East Nordeau Zone on Cartier’s Cadillac Property. Late last year Cartier embarked on an aggressive 600 drill hole, 100,000 metre drill program on its Cadillac property. Cartier has announced...

Phase 1b translational data demonstrate localized ileocolonic target engagement, suppression of inflammatory and fibrotic gene programs, and early clinical response within seven days Encouraging safety profile across 89 subjects supports differentiated, colon-targeted PDE4 approach Translational analyses confirm local suppression of TNF-α, JAK–STAT, NF-κB, MAPK and TGF-β signaling in colon tissue with minimal peripheral immune modulation Data presented at the 21st Congress of the European Crohn’s and Colitis Organization (ECCO) in Stockholm, Sweden Carlsbad, CA, Feb. 23, 2026 (GLOBE NEWSWIRE) — Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon,...

Initial Contract Establishes New $250,000 Annual Recurring Revenue (ARR) Stream With Expansion Potential Exceeding $1 Million Agreement Reflects Continued Enterprise Revenue Momentum NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) — Our Bond, Inc. (“Bond”) (NASDAQ: OBAI), the creator of the world’s first AI-powered Preventative Personal Security platform adopted by leading multinational companies, today announced the execution of a phase 1 commercial agreement valued at approximately $250,000 with one of the world’s five largest pharmaceutical companies, an organization with a market capitalization exceeding $300 billion. The agreement covers 5,000 of the customer’s 100,000 employees across various functions and locations, initially in the USA, as part of a 24/7 full workforce coverage protection concept. This establishes a new recurring...

Experienced AI and enterprise IT operations leader joins Company to accelerate scalable growth, strengthen security architecture, and advance next-generation cyber software innovation Scottsdale, Ariz., Feb. 23, 2026 (GLOBE NEWSWIRE) — CISO Global, Inc. (NASDAQ: CISO) (“CISO Global” or the “Company”), a provider of AI-powered cybersecurity software and compliance services, today announced the appointment of Dhaval Damania as Executive Vice President of Cybersecurity & IT. This appointment reinforces its continued commitment to operational excellence, innovation, and scalable growth across its next-generation cybersecurity software portfolio. In this role, Damania will lead CISO Global’s cybersecurity and IT operations, with accountability for advancing the Company’s portfolio of AI-powered, proactive cybersecurity software...